| Literature DB >> 35480825 |
Ahmed E Allam1, Yhiya Amen2, Ahmed Ashour2, Hamdy K Assaf1, Heba Ali Hassan3, Islam M Abdel-Rahman4, Ahmed M Sayed5, Kuniyoshi Shimizu6.
Abstract
Natural products and traditional medicine products with known safety profiles are a promising source for the discovery of new drug leads. Natural products as sesame were reported to exhibit potential to protect from COVID-19 disease. In our study, the total methanolic extract of Sesamum indicum L. seeds (sesame) were led to isolation of seven known compounds, five lignan; sesamin 1, sesamolin 2, pinoresinol 3, hydroxymatairesinol 6, spicatolignan 7, together with two simple phenolic compounds; ferulic acid 4 and vanillic acid 5. All isolated compounds were evaluated in silico against three important SARS-CoV-2 protein targets; main protease (Mpro), papain-like protease (PLpro) and RNA-dependent RNA polymerase (RdRp) which possessed crucial role in replication and proliferation of the virus inside the human cell. The results revealed that compound 6 has the high affinity against the three main proteins, specially towards the SARS-CoV-2 Mpro that exceeded the currently used SARS-CoV-2 Mpro inhibitor darunavir as well as, exhibiting a similar binding energy at SARS CoV-2 PLpro when compared with the co-crystallized ligand. This activity continued to include the RdRp as it displayed a comparable docking score with remdesivir. Inferiorly, compounds 1 and 2 showed also similar triple inhibitory effect against the three main proteins while compound 7 exhibited a dual inhibitory effect against SARS CoV-2 PLPro and RdRp. Further molecular dynamic simulation experiments were performed to validate these docking experiments and to calculate their binding free energies (ΔGs). Compounds 1, 2, 3, 6, and 7 showed comparable binding stability inside the active site of each enzyme with ΔG values ranged from -4.9 to -8.8 kcal mol-1. All the compounds were investigated for their ADME and drug likeness properties, which showed acceptable ADME properties and obeying Lipinski's rule of five parameters. It can be concluded that the isolated compounds from sesame lignans could be an alternative source for the development of new natural leads against COVID-19. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35480825 PMCID: PMC9034212 DOI: 10.1039/d1ra03937g
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Structure of the isolated compounds.
Fig. 2Docking results of compound 3 in the active site of SARS-CoV-2 main protease (6LU7). (A) Validation of docking procedure showing good matching between crystallized (yellow) and docked (blue) ligands. (B) Docking pose of compound 6. (C) 2D interactions of compound 6.
Receptor interactions and binding energies of the sesame isolated compounds, darunavir and N3 inhibitor into the N3 inhibitor binding site of SARS CoV-2's Mpro
| No. | Drug |
| RMSD_refine | Amino acid bond | Distance Å |
|
|---|---|---|---|---|---|---|
| 1 | Sesamin | −6.7157 | 1.2904 | Gln 189/H-donor | 3.25 | −0.7 |
| Thr 190/H-donor | 3.12 | −0.7 | ||||
| His 41/pi-H | 4.55 | −0.8 | ||||
| Gln 189/pi-H | 4.32 | −0.6 | ||||
| 2 | Sesamolin | −6.829 | 1.6894 | Gln 189/H-donor | 3.24 | −0.5 |
| Thr 190/H-donor | 3.21 | −1 | ||||
| Gln 189/pi-H | 4.42 | −0.6 | ||||
| 3 | Pinoresinol | −6.463 | 1.2304 | Thr 24/H-donor | 2.79 | −0.6 |
| Thr 26/pi-H | 4.51 | −1.2 | ||||
| 4 | Ferulic acid | −5.3292 | 0.9729 | Glu 199/H-donor | 2.89 | −4.2 |
| Thr 190/H-acceptor | 3.46 | −0.7 | ||||
| 5 | Vanillic acid | −4.8624 | 1.3641 | Glu 166/H-donor | 2.86 | −4.3 |
| Thr 190/H-acceptor | 3.31 | −1.2 | ||||
| Gln 189/pi-H | 3.55 | −0.5 | ||||
| 6 | Hydroxymatairesinol | −7.4674 | 1.348 | Met 165/H-donor | 3.21 | −1.6 |
| Ser 144/H-donor | 3.15 | −0.6 | ||||
| Gly 143/H-acceptor | 3.26 | −0.5 | ||||
| 7 | Spicatolignan | −6.7403 | 1.6428 | Glu 166/H-donor | 2.88 | −4.3 |
| Thr 190/H-acceptor | 3.42 | −0.8 | ||||
| 8 | Darunavir | −7.1034 | 1.607 | Gln 189/H-donor | 2.9 | −0.5 |
| Glu 166/H-donor | 3.33 | −0.6 | ||||
| Cys 145/H-donor | 4.09 | −0.8 | ||||
| 9 | N3 | −8.4526 | 1.6031 | Thr 190/H-donor | 2.97 | −2.3 |
| Glu 166/H-donor | 2.85 | −4.5 | ||||
| Gln 189/H-donor | 2.87 | −4.8 | ||||
| His 163/H acceptor | 2.71 | −4.3 | ||||
| His 164/H-donor | 2.94 | −3.7 | ||||
| His 41/pi-H | 3.89 | −0.8 |
S: the score of a compound placement inside the protein binding pocket.
RMSD_refine: the root-mean-squared-deviation (RMSD) between the predicted pose and those of the crystal one (after and before refinement process, respectively).
Docking results of the isolated compounds with SARS CoV-2 papain-like protease 6WUU
| No. | Compound |
| RMSD_refine |
|---|---|---|---|
| 1 | Sesamin | −6.5524 | 1.5919 |
| 2 | Sesamolin | −6.454 | 1.3248 |
| 3 | Pinoresinol | −6.5131 | 1.3406 |
| 4 | Ferulic acid | −4.8177 | 1.4256 |
| 5 | Vanillic acid | −4.6805 | 1.3721 |
| 6 | Hydroxymatairesinol | −7.2085 | 1.348 |
| 7 | Spicatolignan | −6.6183 | 1.7336 |
S: the score of a compound placement inside the protein binding pocket.
RMSD_refine: the root-mean-squared-deviation (RMSD) between the predicted pose and those of the crystal one (after and before refinement process, respectively).
Fig. 3Docking results of compound 3 in the active site of SARS-CoV-2 papain-like protease (6WUU). (A) Validation of docking procedure showing good matching between crystallized and docked ligands. (B) Docking pose of compound 6. (C) 2D interactions of compound 6.
Receptor interactions and binding energies of compound 6 and VER250 into the binding site of SARS CoV-2 papain-like protease 6WUU
| Compound |
| Amino acid residue | Type of binding | Distance Å |
|
|---|---|---|---|---|---|
| Hydroxymatairesinol | −7.2085 | Met 208 | H-donor | 3.14 | −1.5 |
| Asp 164 | H-donor | 2.94 | −0.9 | ||
| Arg 166 | H-acceptor | 3.3 | −0.7 | ||
| VER 250 | −7.2103 | ASP 164 | H-donor | 2.84 | −7 |
| Tyr 268 | H-donor | 2.72 | −11.6 | ||
| Cys 270 | H-donor/acceptor | 3.37 | −0.5 | ||
| Gly 163 | H-donor/acceptor | 3.05 | −4.4 | ||
| Gly 271 | H-donor/acceptor | 2.84 | −0.8 | ||
| Pro247 | Pi-H | 4.5 | −0.6 |
S: the score of a compound placement inside the protein binding pocket.
Fig. 4Docking results of compound 3 in the active site of SARS-CoV-2 RdRp (7BV2). (A) Validation of docking procedure showing good matching between crystallized and docked ligands. (B) Docking pose of compound 6. (C) 2D interactions of compound 6.
Docking results of the compounds and remdesivir with SARS CoV-2 RdRp (7BV2)
| No. | Compound |
| RMSD_refine |
|---|---|---|---|
| 1 | Sesamin | −7.348 | 1.4626 |
| 2 | Sesamolin | −6.9807 | 1.5327 |
| 3 | Pinoresinol | −6.3295 | 1.5142 |
| 4 | Ferulic acid | −5.3733 | 1.024 |
| 5 | Vanillic acid | −5.0486 | 0.6399 |
| 6 | Hydroxymatairesinol | −7.0179 | 1.4883 |
| 7 | Spicatolignan | −6.5373 | 1.1902 |
| Control | Remdesivir | −7.2069 | 1.0485 |
S: the score of a compound placement inside the protein binding pocket.
RMSD_refine: the root-mean-squared-deviation (RMSD) between the predicted pose and those of the crystal one (after and before refinement process, respectively).
Receptor interactions and binding energies of compound hydroxymatairesinol and remdesivir into the binding site of SARS CoV-2 RdRp (7BV2)
| Compound |
| Amino acid residue | Type of binding | Distance Å |
|
|---|---|---|---|---|---|
| Hydroxymatairesinol | −7.0179 | Asp760 | H-donor | 3.02 | −3 |
| U 10 | H-acceptor | 3.53 | −0.5 | ||
| U 20 | H-Pi | 3.92 | −0.9 | ||
| Asp 623 | Pi-H | 4.6 | −0.5 | ||
| Remdesivir | −7.2069 | Asp760 | H-donor | 3.31 | −0.9 |
| U 20 | H-donor | 2.95 | −1.8 | ||
| U 10 | H-donor/acceptor | 3.06 | −1.8 | ||
| Asn691 | H-acceptor | 3.1 | −1.5 | ||
| U 20 | Pi–Pi | 3.83 | 0 |
S: the score of a compound placement inside the protein binding pocket.
Fig. 5RMSDs of compounds 1, 2, 3, 6, and 7 inside the active sites of Mpro, PLpro, and RdRp during 50 ns of MDSs.
Lipinski's rule of five for drug-likeness analysis of the compounds
| No | Name | Lipinski's rule of five | Drug-likeness | ||||
|---|---|---|---|---|---|---|---|
| Molecular weight (g mol−1) | Lipophilicity (log | Hydrogen bond donors | Hydrogen bond acceptor | No. of rule violations | |||
| Less than 500 dalton | Less than 5 | Less than 5 | Less than 10 | Less than 2 violations | Lipinski's rule follows | ||
| 1 | Sesamine | 354.35 | 3.46 | 0 | 6 | 0 | Yes |
| 2 | Sesamoline | 386.35 | 3.48 | 1 | 8 | 0 | Yes |
| 3 | Pinoresinol | 358.39 | 2.67 | 2 | 6 | 0 | Yes |
| 4 | Ferulic acid | 194.18 | 1.62 | 2 | 4 | 0 | Yes |
| 5 | Vanillic acid | 168.15 | 1.4 | 2 | 4 | 0 | Yes |
| 6 | Hydroxymatairesinol | 374.38 | 2.53 | 3 | 7 | 0 | Yes |
| 7 | Spicatolignan | 372.37 | 2.58 | 3 | 7 | 0 | Yes |
Calculated physicochemical parameters of the compoundsa
| No | Compound | MW (g mol−1) | WLOGP | TPSA |
| Water solubility silicos-IT class |
|---|---|---|---|---|---|---|
| 1 | Sesamine | 354.35 | 2.57 | 55.38 | 0.55 | Moderately soluble |
| 2 | Sesamoline | 386.35 | 1.67 | 84.84 | 0.55 | Soluble |
| 3 | Pinoresinol | 358.39 | 2.54 | 77.38 | 0.55 | Moderately soluble |
| 4 | Ferulic acid | 194.18 | 1.39 | 66.76 | 0.85 | Soluble |
| 5 | Vanillic acid | 168.15 | 1.1 | 66.76 | 0.85 | Soluble |
| 6 | Hydroxymatairesinol | 374.38 | 1.86 | 105.45 | 0.55 | Moderately soluble |
| 7 | Spicatolignan | 372.37 | 2.28 | 105.45 | 0.56 | Soluble |
MW, molecular weight; TPSA, topological polar surface area; WLOGP, n-octanol/water partition coefficient (atomistic method); F, Abbott bioavailability scores.
Binding free energies (ΔG) of with docking scores <−6 kcal mol−1
| No. | Compound | Δ | Average RMSD (Å) | ||||
|---|---|---|---|---|---|---|---|
| Mpro | PLpro | RdRp | Mpro | PLpro | RdRp | ||
| 1 | Sesamin | −7.1 | −4.9 | −8.4 | 4.6 | 8.3 | 2.3 |
| 2 | Sesamolin | −6.8 | −5.0 | −7.3 | 5.2 | 6.2 | 3.9 |
| 3 | Pinoresinol | −5.2 | −6.9 | −8.8 | 7.4 | 3.9 | 2.9 |
| 6 | Hydroxymatairesinol | −8.3 | −8.5 | −7.3 | 2.8 | 2.2 | 3.8 |
| 7 | Spicatolignan | −8.0 | −6.5 | −6.6 | 4.1 | 4.9 | 4.8 |